Dr. Randi Isaacs' upcoming presentation at the KidneyCAN 7th Annual Kidney Cancer Research Summit highlights Werewolf's innovation in conditionally activated therapeutics, which could enhance ...
ILKN421H is a novel lipid nanoparticle (LNP)-formulated mRNA encoding a non-alpha HSA–IL-2v fusion protein and dominantly expressed in lymphoid organs after IV injection. ILKN421H selectively expanded ...
The FDA approval of denileukin diftitox (Lymphir) marked a significant shift in this paradigm. As a first-in-class immunotoxin, it employs a dual-action mechanism: directly targeting interleukin-2 (IL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback